Merck fails to win FDA panel backing for Vytorin heart claim

(Reuters) - Merck & Co should not be allowed to claim that its cholesterol-lowering drug Vytorin reduces the risk of heart attacks and strokes in patients with coronary heart disease, an advisory committee to the U.S. Food and Drug Administration concluded on Monday.

http://ift.tt/1Z96J8s

from Reuters: Health News
via animenewspro